2023
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson K, Kakara M, Zuroff L, Bennett J, von Büdingen H, Carruthers R, Edwards K, Fallis R, Giacomini P, Greenberg B, Hafler D, Ionete C, Kaunzner U, Lock C, Longbrake E, Pardo G, Piehl F, Weber M, Ziemssen T, Jacobs D, Gelfand J, Cross A, Cameron B, Musch B, Winger R, Jia X, Harp C, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2207291120. PMID: 36634138, PMCID: PMC9934304, DOI: 10.1073/pnas.2207291120.Peer-Reviewed Original ResearchConceptsEarly disease activityDisease activityCD8 T cellsT cellsCD20 therapyPeripheral blood mononuclear cellsCellular immune profilesNew disease activityMS disease activityT cell poolMultiple sclerosis patientsAnti-inflammatory profileBlood mononuclear cellsTreatment-associated changesMultiparametric flow cytometryCentral nervous systemFurther dosingRepeat infusionsImmune profileMS patientsSclerosis patientsValidation cohortMononuclear cellsRelapse developmentImmune cascade
2020
Sex effects across the lifespan in women with multiple sclerosis
Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances In Neurological Disorders 2020, 13: 1756286420936166. PMID: 32655689, PMCID: PMC7331774, DOI: 10.1177/1756286420936166.Peer-Reviewed Original ResearchMultiple sclerosisCentral nervous system disordersMS disease activityLong-term prognosisEffect of pregnancyNervous system disordersMS careMS relapsesDisability progressionDisease activityMS riskOvarian agingRelapse riskReproductive yearsSexual dysfunctionDMT useSex effectsMS susceptibilitySystem disordersPregnancyReproductive agingEffects of sexFamily planningWomenMale sex ratio
2019
Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
Ramaglia V, Sheikh-Mohamed S, Legg K, Park C, Rojas OL, Zandee S, Fu F, Ornatsky O, Swanson EC, Pitt D, Prat A, McKee TD, Gommerman JL. Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. ELife 2019, 8: e48051. PMID: 31368890, PMCID: PMC6707785, DOI: 10.7554/elife.48051.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMS disease activityT-cell phenotypeMass cytometryTypes of lymphocytesMultiple sclerosis lesionsNatalizumab cessationDisease activityMS patientsInflammatory lesionsImmune cellsSpinal cordLesion morphometryMS lesionsB cellsLesion typeSclerosis lesionsLesionsBlood vesselsCell phenotypeFunctional stateCytometryCellular contentCell-cell interactionsPhenotype
2011
What happens when natalizumab therapy is stopped?
Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Review Of Neurotherapeutics 2011, 11: 1247-1250. PMID: 21864070, DOI: 10.1586/ern.11.109.Peer-Reviewed Original ResearchMS disease activityDisease activityActive diseaseNatalizumab cessationTreatment interruptionMultiple sclerosisBaseline levelsSimilar disease activityProgressive multifocal leukoencephalopathyNatalizumab exposureNatalizumab therapyNatalizumab treatmentMultifocal leukoencephalopathyMS patientsMRI measuresMS treatmentEvidence of reboundDiseaseElimination kineticsNatalizumabIntegrin antagonistsTreatmentPatientsCessationLeukoencephalopathy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply